Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥399 | ¥315 | ¥556 | ¥560 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | ¥153 | ¥127 | ¥179 | ¥157 |
| Gross Profit | ¥245 | ¥188 | ¥377 | ¥403 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | ¥50 | ¥113 | ¥132 | ¥95 |
| G&A Expenses | ¥181 | ¥430 | ¥279 | ¥180 |
| SG&A Expenses | ¥181 | ¥430 | ¥339 | ¥217 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥60 | ¥38 |
| Other Operating Expenses | -¥14 | ¥0 | -¥139 | ¥30 |
| Operating Expenses | ¥217 | ¥542 | ¥332 | ¥343 |
| Operating Income | ¥29 | -¥354 | -¥77 | ¥60 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -¥11 | ¥31 | ¥29 | ¥23 |
| Pre-Tax Income | ¥18 | -¥323 | -¥48 | ¥83 |
| Tax Expense | -¥6 | -¥8 | ¥49 | ¥42 |
| Net Income | ¥24 | -¥315 | -¥75 | ¥56 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥2 | ¥36 | ¥32 | ¥26 |
| Interest Expense | ¥14 | ¥4 | ¥3 | ¥3 |
| Depreciation & Amortization | ¥26 | ¥38 | ¥41 | ¥38 |
| EBITDA | ¥57 | -¥281 | -¥3 | ¥124 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |